Connor, Clark & Lunn Investment Management Ltd. Intellia Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $7.11 Million - $9.46 Million	131,876 Added 463.05%	160,356 $8.97 Million
Q2 2022 Aug 05, 2022	BUY	$38.49 - $76.21 $690,626 - $1.37 Million	17,943 Added 170.29%	28,480 $1.47 Million
Q1 2022 May 12, 2022	BUY	$58.27 - $118.99 $613,990 - $1.25 Million	10,537 New	10,537 $766,000
Q4 2021 Feb 10, 2022	SELL	$100.76 - $138.36 $6.22 Million - $8.54 Million	-61,732 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$132.37 - $176.78 $579,780 - $774,296	-4,380 Reduced 6.63%	61,732 $8.28 Million
Q2 2021 Aug 12, 2021	BUY	$60.88 - $161.91 $3.07 Million - $8.16 Million	50,380 Added 320.24%	66,112 $10.7 Million
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $732,953 - $1.32 Million	15,732 New	15,732 $1.26 Million

Others Institutions Holding NTLA

# of Institutions

315

Shares Held

90.6M

Call Options Held

442K

Put Options Held

880K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

12.3M
Shares

$126 Million
2.39% of portfolio
Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$99.4 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$99 Million
0.0% of portfolio
State Street Corp Boston, MA

5.14M
Shares

$53.1 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.95M
Shares

$51.1 Million
3.75% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $784M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account